We are an oncology drug discovery company developing precision medicines using our proprietary N-myristoyltransferases (NMT) platform to build a pipeline of programmes. These are based on proprietary chemical inhibitors of NMT (NMTi), both as small molecule drugs and as cancer cell type selective novel antibody drug conjugate (ADC) payloads.
Building on world leading research into the structure and function of NMT by our academic founder Professor Ed Tate we have developed highly potent and selective small molecule inhibitors of this enzyme. Using these as tools we have made breakthrough discoveries that reveal how inhibitors of NMT deliver a unique mechanism of specific cancer cell killing.
Led by a team of internationally renowned scientists and drug developers with an outstanding track record of commercial and academic successes.
To unlock the potential of N-myristoyltransferase (NMT) as a therapeutic target and develop precision oncology medicines for patients with cancers that are difficult to treat.
High-resolution snapshots of human N-myristoyltransferase in action
- Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi 17 April 2023 - New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi)…
- Myricx Pharma Announces Senior Team Expansion with Appointment of CMO, and Heads of Biology and Bioinformatics 22 February 2022 - Zahid Bashir MB BS, MSc joins as Chief Medical Officer, bringing significant clinical haematology and oncology experience, having led the…